+1-518-621-2074 | US-Canada Toll Free Contact Us

Scientists Take Step Ahead for Definitive Heart Regeneration Therapies

about us

Published on : Aug 06, 2019

A new research paper is published in the Nature Biotechnology and is partially funded by the British Hearth Foundation (BHF). According to this research paper, a combination of hear cells that are derived from the human stem cells are the key to develop the much needed treatment for cardiac failure.

Scientists working on the research have discovered that by transplanting an area of the affected tissue with mix of both supportive cells and heart muscle cells can help in recovery of organs. These cells are taken from the exterior layer of the heart wall and help in organ recovery after the event of heart attack.

Since many years, the researchers have been trying to use stem cells to recover the damage of heart. These efforts have been largely fruitless due to the fact that most of the transplanted cells become useless and die after a few days.

Epicardial Cells Key for Heart Regeneration

However, now the research team from the University of Cambridge, led by Dr. Sanjay Sinha have used supportive epicardial cells for the treatment. The research team is working in collaboration with the team from the University of Washington. Scientists have derived the epicardial cells from human stem cells. These cells allow the transplanted heart cells to live longer.

The researchers have used three dimensional heart tissues for the purpose of this test. These tissues were developed in the lab from stem cells to check the cell combination. The test results showed that these supportive epicardial cells allowed the muscles cells of the heart to mature and develop. They also helped in enhancing the ability of the heart muscle cells to relax and contract.

The team now strives to understand how these supportive epicardial cells aid in driving the heart regeneration. The team believes that gaining insightful knowledge about this subject is key to develop definitive heart regenerative therapies and bring them to clinical trials.